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Abstract
Introduction: Severe trauma with concomitant chest injury is frequently associated with acute lung failure (ALF).
This report summarizes our experience with extracorporeal lung support (ELS) in thoracic trauma patients treated
at the University Medical Center Regensburg.
Methods: A retrospective, observational analysis of prospectively collected data (Regensburg ECMO Registry
database) was performed for all consecutive trauma patients with acute pulmonary failure requiring ELS during a
10-year interval.
Results: Between April 2002 and April 2012, 52 patients (49 male, three female) with severe thoracic trauma and
ALF refractory to conventional therapy required ELS. The mean age was 32 ± 14 years (range, 16 to 72 years).
Major traffic accident (73%) was the most common trauma, followed by blast injury (17%), deep fall (8%) and blunt
trauma (2%). The mean Injury Severity Score was 58.9 ± 10.5, the mean lung injury score was 3.3 ± 0.6 and the
Sequential Organ Failure Assessment score was 10.5 ± 3. Twenty-six patients required pumpless extracorporeal
lung assist (PECLA) and 26 patients required veno-venous extracorporeal membrane oxygenation (vv-ECMO) for
primary post-traumatic respiratory failure. The mean time to ELS support was 5.2 ± 7.7 days (range, <24 hours to
38 days) and the mean ELS duration was 6.9 ± 3.6 days (range, <24 hours to 19 days). In 24 cases (48%) ELS
implantation was performed in an external facility, and cannulation was done percutaneously by Seldinger’s
technique in 98% of patients. Cannula-related complications occurred in 15% of patients (PECLA, 19% (n = 5);
vv-ECMO, 12% (n = 3)). Surgery was performed in 44 patients, with 16 patients under ELS prevention. Eight
patients (15%) died during ELS support and three patients (6%) died after ELS weaning. The overall survival rate
was 79% compared with the proposed Injury Severity Score-related mortality (59%).
Conclusion: Pumpless and pump-driven ELS systems are an excellent treatment option in severe thoracic trauma
patients with ALF and facilitate survival in an experienced trauma center with an interdisciplinary treatment
approach. We encourage the use of vv-ECMO due to reduced complication rates, better oxygenation and best
short-term outcome.
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Introduction
Severe multiple trauma is often associated with traumatic
lung injury and presents with a wide spectrum of severity.
In recent databases, patients with multiple trauma are
reported to suffer from associated chest injury in nearly
50% of cases [1]. However, only a minority of patients
develop post-traumatic respiratory insufficiency that
mandates intubation and mechanical ventilation [2].
Generally, the management of both blunt and penetrating
thoracic injuries is supportive and should aim to mini-
mize the systemic inflammatory response syndrome and
its progression to acute lung failure (ALF) or acute
respiratory distress syndrome (ARDS) [3]. Nevertheless,
ALF and ARDS are severe and common complications of
major thoracic trauma [4]. ALF is characterized by a life-
threatening impairment of the pulmonary gas exchange,
resulting in hypoxia, hypercapnia and respiratory acidosis
[5]. But despite recent advantages in critical manage-
ment, severe thoracic injuries with ALF or cardiopul-
monary insufficiency present a challenge and are still
associated with high morbidity and mortality [6,7]. Con-
ventional mechanical ventilation strategies are the main-
stay of treatment for ALF associated with thoracic
trauma [8]. But trauma patients with critical respiratory
insufficiency (life-threatening hypoxemia and/or severe
hypercapnia/acidosis) refractory to optimized conven-
tional treatment strategies may finally benefit from a res-
cue extracorporeal gas exchange [9].
Extracorporeal lung support (ELS) devices such as
pumpless extracorporeal lung assist (PECLA) or extra-
corporeal membrane oxygenation (ECMO) may be used
as a temporary replacement for the damaged lungs in
order to provide sufficient ventilation, oxygenation,
improvement of hypercapnia and time for recovery of
the lungs, after all treatment options including invasive
ventilation have failed [3,6,10,11]. Nevertheless, the
impact of ECMO support in patients with severe pul-
monary failure due to traumatic life-threatening injuries
remains controversial especially due to the risk of bleed-
ing complications, and its application is limited to a few
experienced centers [2,12].
This institutional report summarizes prospectively col-
lected data and describes our interdisciplinary experi-
ence with ELS including PECLA and veno-venous
extracorporeal membrane oxygenation (vv-ECMO) in
severe thoracic trauma patients with ALF treated at the
University Medical Center Regensburg during a 10-year
interval.
Patients and methods
Patients and indications
This was a retrospective analysis of prospectively col-
lected data from the Regensburg ECMO Registry.
Between April 2002 and April 2012 a total of 52 patients
with severe trauma and concomitant chest injury caus-
ing ALF with the need for ELS were interdisciplinary
treated at the University Medical Center Regensburg
and included in this study sample. The study had a ret-
rospective design and was approved by the local ethics
committee of the University Medical Center Regensburg.
The requirement of individual patient consent was
waived because of the study’s retrospective design and
data collection from routine care. Our Institutional
Review Board waived the necessity of approval for the
data report.
We describe our institutional experience with both
pumpless and pump-driven devices in severe trauma
patients. Patient characteristics, laboratory data, ventilation
parameters, ELS therapy, surgical procedures and clinical
outcome data were recorded and evaluated. Severe post-
traumatic ALF was defined by partial pressure of arterial
oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio <80
mmHg, a maximum positive end-expiratory pressure
(18 cmH2O) and persistent respiratory acidosis (pH <7.25)
despite optimized mechanical ventilation and optimization
of conservative treatment options. Before implantation of
an ELS device, a trial to improve the pulmonary gas
exchange was conducted following the institutional proto-
col, including lung recruitment maneuvers, inhalation of
vasodilators (nitric oxide, prostacyclin), kinetic therapy
(prone positioning) and high-frequency oscillatory ventila-
tion depending on the patient’s status [13]. ALF was trea-
ted either with PECLA or with vv-ECMO. Three patients
with persisting cardiopulmonary failure despite improved
gas exchange were switched to secondary veno-arterial
ECMO after primary ELS (1× PECLA, 2× vv-ECMO).
During the study period four trauma patients with cardio-
pulmonary failure required primary implantation of a
veno-arterial ECMO for hemodynamic stabilization. These
patients were excluded from this analysis. The primary
endpoint was survival to discharge from our hospital.
Techniques of extracorporeal lung support
Until 2008, patients with ALF were treated with PECLA
(Novalung GmbH, Heilbronn, Germany) developed in
1996 by Philipp and colleagues [14]. Technical data and
the implantation technique have been described in detail
by our institution [11,15]. In principle, the PECLA is an
artificial arterio-venous shunt with an interposed extracor-
poreal membrane oxygenator without the need of a pump
[16]. The prerequisite is normal left ventricular function
and an absence of a distinctive peripheral arteriosclerosis.
The purpose of this method is the effective elimination of
carbon dioxide with a modest increase in arterial oxygena-
tion and rapid normalization of respiratory acidosis.
During the study period we changed our ELS treatment
regime due to developing more experience with minia-
turized vv-ECMO in patients with respiratory failure
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(Figure 1). We did not use classic vv-ECMO in the phase
between 2002 and 2008, since during that period avail-
able systems were characterized by high priming volumes
and increased demand for anticoagulation, which we felt
were not suitable in patients presenting with severe
trauma. The advantage of PECLA use in these patients
was lower anticoagulation and avoidance of stress to
blood components by the pumpless technique. The
choice of technique was not influenced by a specific indi-
cation, but by the specific supposed suitability of the
device. After impressive technical development and min-
iaturization of vv-ECMO systems (centrifugal pump, low
priming volume, smaller cannulas), we predominantly
switched to such a technique. Therefore, since 2008 we
primarily use vv-ECMO in trauma patients with ALF
refractory to conventional treatment strategies for
improvement of gas exchange.
ECMO provides sufficient extracorporeal oxygenation
and removal of carbon dioxide. The extracorporeal device
consisted of a membrane oxygenator and a centrifugal
pump (Permanent Life Support System; Maquet Cardio-
pulmonary AG, Hirlingen/Rastatt, Germany). Since 2009,
five patients were also provided with a single dual-lumen
cannula inserted via the right jugular vein into the super-
ior and inferior caval vein. The whole system is coated
with heparin, hence a pronounced systemic anticoagula-
tion is not necessary [13]. More details of vv-ECMO were
already presented in previous studies from our working
group [5,13,17]. Miniaturized veno-arterial ECMO was
accomplished in patients with cardiopulmonary failure
despite ELS in an emergency setting via the femoral vein
and the femoral artery (n = 3). In all ELS devices, heparin-
coated cannulas and circuits were used to decrease the
systemic heparin dosage and to reduce post-traumatic
bleeding complications [18].
Patient management under extracorporeal lung support
After applying ELS, for patients with vv-ECMO the pump
flow was adapted to ensure adequate oxygenation and to
achieve protective mechanical ventilation (tidal volume
≤6 ml/kg predicted body weight, peak inspiratory pres-
sure < 28 cmH2O). For patients under ELS mechanical
ventilation, the parameters were reduced as soon as pos-
sible in order to perform lung-protective ventilation. For
this purpose, FiO2, tidal volume and minute ventilation
were stepwise decreased with the aim of a minimum
PaO2 of 65 to 75 mmHg and a modest hypercapnia (par-
tial pressure of arterial carbon dioxide 40 to 50 mmHg,
except severe brain injury). Spontaneous breathing with
assisted ventilation (positive airway pressure) was accom-
plished after 48 to 72 hours when clinical and radiologi-
cal findings indicated the end of the vulnerable phase of
acute lung injury. The mean arterial pressure was main-
tained between 60 and 75 mmHg by administering vaso-
pressors continuously, especially in patients treated with
PECLA. Intravenous heparin was applied to hold a partial
thromboplastin time of about 50 to 60 seconds in PECLA
patients without elevated bleeding risk. Our anticoagula-
tion protocol used for vv-ECMO is also based on contin-
uous heparin infusion, beginning with 600 IU/hour. We
intend to reach a partial thromboplastin time of 40 to
50 seconds (control of partial thromboplastin time every
8 hours). This algorithm was individually modified with
increasing hemorrhagic risk. In patients with high risk of
further bleeding complications or evidence of relevant
intracranial bleeding (Glasgow Coma Scale <9 and/or
pathologic computed tomography scan), we avoided
heparin for a certain period (≤48 hours). After bleeding
control by repeated computed tomography scan, we
slowly started to give heparin with a partial thromboplas-
tin time range of 40-50 seconds.
Additional laboratory investigations included further
coagulation and clotting parameters, hemoglobin and liver
enzymes. In the early period (≤24 hours) arterial blood
gases were drawn frequently (every 4 hours), while in the
later period blood gases were analyzed every 8 hours.
Basic monitoring of the lower extremities included contin-
uous limb pulsoximetry distal to the arterial cannulation
site, determination of serum lactate and creatinine kinase
levels as well as clinical inspection for any signs of
restricted perfusion and/or ischemia.
After respiratory and/or hemodynamic stabilization
with adequate gas exchange, weaning from vv-ECMO
was initiated by decreasing the extracorporeal blood flow
to 1.5 l/minute. In addition, gas flow was scaled down
(ECMO withdrawal trial). Afterward the system was
switched off and if no marked deterioration of gas
Figure 1 Distribution of both extracorporeal lung support
systems implanted during the study period. PECLA, pumpless
extracorporeal lung assist; vv-ECMO, veno-venous extracorporeal
membrane oxygenation.
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exchange and/or hemodynamics were observed within
2 hours, the ELS system was disconnected. Decannula-
tion was achieved in most cases by simple manual com-
pression of the vessel access site. Only in four patients
was surgical removal of the cannulas (all arterial)
necessary.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS
Inc., Chicago, IL, USA) for Windows (Microsoft Corp.,
Redmond, WA, USA) and Stata SE 10.1 for Windows
(StatCorp., College Station, TX, USA). Descriptive statis-
tics were used to describe patient characteristics through-
out the study. Means and standard deviations were
computed for normally distributed continuous variables,
whereas medians and interquartile ranges (25th to 75th)
were used to describe non-normally distributed continu-
ous data. Student’s t test was performed for comparison
of normally distributed data and the Mann-Whitney U
test was used for non-normally distributed data. Catego-
rical variables are presented as frequency distributions
(n) and simple percentages (%). Fisher’s exact test was
performed for categorical data in a 2×2 table or the chi-
square test in a 2×3 table. P < 0.05 was considered statis-
tically significant.
Results
Demographic data
The study sample included 52 patients (49 male, three
female) with a mean age of 32 ± 14 years (range, 16 to
73 years), with characteristics as presented in Table 1.
Only trauma patients with concomitant chest injury
were enrolled and all patients suffered from severe post-
traumatic pulmonary failure that lead to consecutive
hypercapnia and hypoxia refractory to conventional
treatment strategies.
Major traffic accident was the most common trauma
(73%), followed by blast injury/gunshot (17%), deep fall
(8%), and blunt trauma (2%). All patients had multiple
organ injuries. In 30 patients (58%) we observed moderate
to severe head trauma. Within this subgroup, intracranial
hematoma or bleeding was evident in 14 patients. The
mean Injury Severity Score was 58.9 ± 10.5. Cardiopul-
monary resuscitation was performed in 15% (n = 8) of all
patients before implantation of the mechanical assist
device. Acute renal failure requiring temporary renal
replacement therapy was present in eight patients (15%)
prior to ELS implantation. There were 40 (77%) patients
with unilateral or bilateral serial/multiple rib fractures and
concomitant hematothorax and pneumothorax. Additional
post-traumatic or aspiration pneumonia was seen in 29
(56%) patients, causing the need for ELS support. The
mean Lung Injury Score according to Murray was 3.3 ±
0.6 and the mean Sequential Organ Failure Assessment
score was 10.5 ± 3.
Changes of gas exchange and ventilation parameters
All relevant parameters prior to ELS implantation under
maximal ventilator support are listed in Table 2 for all
patients and also for each ELS system. The median PaO2/
FiO2 ratio for all patients was 63 (49 to 101) and was
comparably higher in patients treated with PECLA
(97; 56 to 173) compared with patients treated with
vv-ECMO (54; 48 to 65). No relevant differences were
present regarding the median partial pressure of arterial
carbon dioxide (68 mmHg vs. 67 mmHg). All patients
Table 1 Patient characteristics and different types of extracorporeal lung support
Variable All patients (n = 52) PECLA (n = 26) vv-ECMO (n = 26)
Male gender 49 (94.2) 25 (96) 24 (92)
Age (years) 32 ± 14 34.5 ± 14.3 29.3 ± 13.2
Height (cm) 178.6 ± 7.2 179 ± 6.8 178.2 ± 7.6
Weight (kg) 89.8 ± 20.6 85.8 ± 16.5 93.8 ± 23.6
Body mass index (kg/m2) 28.2 ± 6.1 26.7 ± 4.5 29.6 ± 7.3
Trauma
Traffic accident 38 (73) 17 (65) 21 (81)
Blast injury/gunshot wound 9 (17) 6 (23) 3 (11)
Deep fall 4 (8) 3 (12) 1 (4)
Blunt 1 (2) 0 1 (4)
Prior resuscitation 8 (15.4) 4 (15.4) 4 (15.4)
Acute renal failure prior to ELS 8 (15.4) 4 (15.4) 4 (15.4)
Injury Severity Score 58.9 ± 10.5 57.8 ± 10.9 59.4 ± 11.2
Lung Injury Score 3.3 ± 0.57 3.06 ± 0.65 3.53 ± 0.36
SOFA score 10.5 ± 3 9.2 ± 3 11.8 ± 2.4
Data presented as n (%) or mean ± standard deviation. ELS, extracorporeal lung support; PECLA, pumpless extracorporeal lung assist; SOFA, Sequential Organ
Failure Assessment; vv-ECMO, veno-venous extracorporeal membrane oxygenation.
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had primary respiratory acidosis (median pH 7.25) due to
hypercapnia.
All data regarding gas exchange, ventilation and hemo-
dynamic parameters in the course of time for PECLA as
well as for vv-ECMO are shown in Table 3. In both sys-
tems the median PaO2/FiO2 ratio continuously increased
immediately after initiating the ELS and stayed at an
acceptable level until the ELS was removed (Figure 2). The
median PaO2 values increased in patients treated with vv-
ECMO, whereas there was only a mild increase in patients
treated with PECLA (Figure 3). Otherwise, there was a
decrease regarding the partial pressure of arterial carbon
dioxide in the PECLA group due to effective carbon diox-
ide removal. These facts are mainly caused by the varying
ELS systems used in the patients. In addition, before ELS
implantation all patients had respiratory acidosis with a
median pH of 7.25 (PECLA patients) and 7.21 (vv-ECMO
patients), which rapidly improved to normal pH values
directly after being supported by the extracorporeal device
(Figure 4).
Extracorporeal lung support implantation and
management strategies
Data regarding ELS are presented in Table 4. All patients
had mechanical ventilation before implantation of the
ELS system with a mean time of 3.2 ± 4.1 days. Slightly
more than one-half of the devices were implanted at the
University Medical Center Regensburg (n = 27; 52%) as
well as in outlying hospitals or the battle field (Iraq/
Afghanistan) with ground or air transport to our hospital
(n = 25; 48%). Almost 70% of all patients treated with vv-
ECMO received ELS implantation in an external facility,
in contrast to only 29% of patients treated with PECLA.
All patients underwent peripheral cannulation. In 98% of
patients, cannulation was performed via a percutaneous
approach (Seldinger’s technique). Only in one patient
were both cannulas inserted through an open surgical
access (PECLA). Ultrasonography was performed in all
patients to ensure correct anatomic location prior to ves-
sel puncture. Afterwards the guidewires were inserted
and the cannulas were implanted.
Table 2 Gas exchange and ventilation parameters prior to extracorporeal lung support implantation
Variable All patients (n = 52) PECLA (n = 26) vv-ECMO (n = 26)
PaO2/FiO2 63 (49 to 101) 97 (56 to 173) 54 (48 to 65)
PaO2 (mmHg) 63 (49 to 89) 80 (56 to 99) 54 (48 to 65)
PaCO2 (mmHg) 67 (50 to 87) 68 (50 to 84) 67 (49 to 97)
pH 7.23 (7.16 to 7.38) 7.25 (7.18 to 7.37) 7.21 (7.12 to 7.38)
Arterial oxygen saturation (%) 92 (79 to 97) 96 (83 to 98) 88 (74 to 93)
MV (l/minute) 12 (9 to 14) 12 (9 to 14) 11 (8 to 14)
VT (ml) 516 (438 to 567) 483 (430 to 560) 560 (458 to 613)
MAP (mmHg) 71 (65 to 81) 69 (65 to 80) 71 (65 to 81)
Lactate (mg/dl) 28 (14 to 49) 16 (10 to 30) 38 (21 to 70)
Data presented as median (25th to 75th interquartile range). FiO2, fraction of inspired oxygen; MAP, mean arterial pressure; MV, minute volume; VT, tidal volume;
PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; PECLA, pumpless extracorporeal lung assist; vv-ECMO, veno-venous
extracorporeal membrane oxygenation.
Table 3 Gas exchange, ventilation and hemodynamic parameters in the course of time for both ELS systems
Variable Prior ELS implant After 2 hours 1 day 2 days ELS explant 1 day post
PECLA
PaO2/FiO2 97 (56 to 173) 124 (61 to 147) 135 (83 to 213) 167 (136 to 263) 225 (196 to 283) 236 (198 to 289)
PaO2 (mmHg) 80 (56 to 99) 67 (59 to 92) 76 (68 to 93) 92 (68 to 109) 89 (76 to 99) 93 (68 to 107)
PaCO2 (mmHg) 68 (50 to 84) 46 (41 to 59) 44 (40 to 48) 43 (38 to 57) 42 (37 to 47) 45 (41 to 54)
pH 7.25 (7.18 to 7.37) 7.41 (7.33 to 7.45) 7.44 (7.36 to 7.49) 7.45 (7.4 to 7.48) 7.45 (7.39 to 7.46) 7.42 (7.31 to 7.45)
MV (l/minute) 12 (9 to 14) 8 (6 to 13) 7 (5 to 8) 7 (5 to 9) 9 (8 to 12) 11 (9 to 14)
MAP (mmHg) 69 (65 to 80) 77 (68 to 81) 80 (75 to 90) 85 (74 to 96) 79 (71 to 99) 78 (68 to 85)
vv-ECMO
PaO2/FiO2 54 (48 to 65) 105 (67 to 124) 141 (104 to 186) 158 (127 to 207) 291 (223 to 370) 270 (218 to 323)
PaO2 (mmHg) 54 (48 to 65) 105 (67 to 123) 135 (96 to 177) 148 (106 to 203) 254 (118 to 353) 253 (173 to 288)
PaCO2 (mmHg) 67 (49 to 97) 34 (30 to 39) 34 (31 to 40) 36 (34 to 42) 42 (36 to 44) 43 (40 to 50)
pH 7.21 (7.12 to 7.38) 7.46 (7.4 to 7.52) 7.47 (7.41 to 7.51) 7.46 (7.43 to 7.48) 7.42 (7.38 to 7.46) 7.42 (7.38 to 7.45)
MV (l/minute) 11 (8 to 14) 6 (5 to 7) 4 (3 to 5) 5 (3 to 6) 8 (6 to 11) 12 (9 to 14)
MAP (mmHg) 71 (65 to 81) 79 (68 to 83) 77 (69 to 85) 76 (68 to 82) 76 (71 to 86) 72 (65 to 81)
Data presented as median (25th to 75th interquartile range). ELS, extracorporeal lung support; FiO2, fraction of inspired oxygen; MAP, mean arterial pressure; MV,
minute volume; VT, tidal volume; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; PECLA, pumpless extracorporeal lung
assist; vv-ECMO, veno-venous extracorporeal membrane oxygenation.
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There were no severe system-related complications
(cannula dislocation, ELS dysfunction) during intensive
care transport. The mean time from trauma to installation
of the extracorporeal device was 5.2 ± 7.7 days (median
time 3 days) and varied from <24 hours up to 38 days. In
all patients treated with PECLA, the femoral vein and the
femoral artery were cannulated (median cannula size 17F;
range, 15F to 19F). In 18 (69%) patients treated with
vv-ECMO the venous drainage was obtained from the
femoral and jugular vein, in two (8%) patients also from
the subclavian vein or the contralateral femoral vein (n =
1; 4%). The median cannula size was 21F (range, 17F to
27F). The single double-lumen cannula (Avalon; Maquet,
Rastatt, Germany) was used in five (19%) patients with a
median cannula size of 23F (range, 23F to 27F). The mean
pump flow was 3 ± 0.64 l/minute and was adjusted to
allow protective ventilation and sufficient gas exchange.
Cannula-related complications, including mostly ische-
mia or minor bleeding, occurred in 15% of all patients and
were more frequent in patients with arterial cannulation
(PECLA, 19%) than in those with only venous cannulas
(vv-ECMO, 12%). There was one patient with a need for
Figure 2 Time course of the partial oxygen pressure/fraction of
inspired oxygen ratio during extracorporeal lung support. Time
course of the partial oxygen pressure (PaO2)/fraction of inspired
oxygen (FiO2) ratio during extracorporeal lung support separated
into both systems. Median with 25th to 75th interquartile range.
PECLA, pumpless extracorporeal lung assist; vv-ECMO, veno-venous
extracorporeal membrane oxygenation.
Figure 3 Changes of relevant gas exchange parameters under
extracorporeal lung support. Median with 25th to 75th
interquartile range. CO2, carbon dioxide; O2, oxygen; PECLA,
pumpless extracorporeal lung assist; vv-ECMO, veno-venous
extracorporeal membrane oxygenation.
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lower limb fasciotomy on both sides due to venous
femoral cannulation (left side), but there was no patient
with a need for amputation due to venous or arterial can-
nulation. The overall median length of ICU stay was
22 days and the median stay in our university hospital was
25 days. Afterwards patients were discharged or trans-
ferred to another hospital or rehabilitation center.
Whenever necessary, further operative treatment was
performed before, during or after ELS for life salvage. In
total, surgery was performed in 45 (87%) patients, with
16 (31%) patients under ELS prevention. Nonthoracic
surgical procedures included trauma surgery (that is, sta-
bilization of limb fractures, spine surgery) and general
surgery (that is, abdominal packing, splenectomy). In
patients with intracranial bleeding (n = 14), 11 (79%)
were treated with an external ventricular drainage and
three patients (21%) also underwent neurosurgical cra-
niotomy with evacuation of hematoma. Many patients
had more than one operation during their hospitalization.
In this series we found no relevant, life-threatening
bleeding complications related to secondary nonthoracic
surgery. There were 12 patients with abdominal bleeding,
which could be successfully treated. In eight (15%)
patients, extended thoracic surgical interventions (lung
resection, active bleeding control) were also performed
before or after ELS implantation. No relevant postopera-
tive bleeding complications were noted. During ELS, the
overall transfusion rate of packed red blood cells in all
patients during ELS was of median 3 (range, 0 to 54),
with no significant differences between PECLA (median
3; range, 0 to 12) and vv-ECMO (median 3; range, 0
to 54). Fresh frozen plasma was only needed in one
patient treated with PECLA (n = 14 fresh frozen plasma
units), whereas 10 patients with vv-ECMO required fresh
frozen plasma (median 19 units; range, 1 to 102). One
patient required a total of 54 packed red blood cell units,
102 fresh frozen plasma units and 11 platelet concen-
trates during vv-ECMO for 3 days. This patient died
under ECMO support due to fulminant, diffuse bleeding.
The mean duration of ELS was 6.9 ± 3.6 days and was
slightly, but insignificantly longer in patients treated with
PECLA (7.6 ± 4 days) compared with patients treated
with vv-ECMO (6.3 ± 3.1 days). Two patients with initial
PECLA support were changed to veno-arterial ECMO
because of progressive cardiopulmonary insufficiency.
One patient treated with vv-ECMO developed cardiac
failure, which mandated placement of veno-arterial
ECMO on an emergency basis. All three patients died
due to multiorgan failure. Weaning from ELS was suc-
cessful in 84.6% of all patients. Overall in-hospital mor-
tality was 21% (n = 11) with a slightly higher mortality
rate in patients with PECLA (23%) than in patients with
vv-ECMO (19%). Leading causes of death were multior-
gan failure (n = 9), fulminant bleeding (n = 1) and cere-
bral hypoxia and bleeding with entrapment (n = 1). No
death was a direct related result of the ELS support with
respect to vessel cannulation or our anticoagulation
regime.
Discussion
The mortality of patients with acute respiratory failure
remained high throughout recent years and was reported
to be approximately 27 to 45% [19]. On the other hand,
the ARDS mortality rate in both blunt and penetrating
trauma patients decreased over time [20]. ECMO has the
unique potential to support gas exchange without caus-
ing further lung damage from invasive positive pressure
ventilation (barotrauma) in adult patients with fulminant
respiratory failure and may improve patient survival [21].
ECMO may thus provide an additional treatment modal-
ity in patients with severe traumatic lung injury with ALF
that does not respond to conventional treatment and
ventilatory regimes [8]. Recently, ECMO therapy also
Figure 4 Improvement and normalization of arterial pH
immediately after extracorporeal lung support implantation in
both groups. Median with 25th to 75th interquartile range. PECLA,
pumpless extracorporeal lung assist; vv-ECMO, veno-venous
extracorporeal membrane oxygenation.
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presents a rescue therapy in severe trauma patients with
concomitant chest injury suffering from refractory ALF
when conventional therapies have been exhausted [2,18].
In previous reports, ELS devices have been safely used in
adult trauma patients with multiple injuries and severe
pulmonary failure with an improved survival after early
implementation [9]. Quick encouragement for and short
duration of ECMO for the temporary management of gas
exchange has been reported to improve survival rates in
trauma patients with ARDS [12]. However, to our knowl-
edge in the recent literature there are only case reports
or studies with limited numbers of patients.
In this report we describe our interdisciplinary experience
with ELS including PECLA and vv-ECMO in severe thor-
acic trauma patients with ALF. In particular, this study
sample deals with the largest number of patients who were
treated with this special management of ELS therapy.
The main findings of our study are as follows. First, ELS
enabled a rapid and sustained improvement of oxygena-
tion, removal of carbon dioxide and correction of respira-
tory acidosis. In addition, our data demonstrate that ELS
can provide advanced lung-protective ventilation strategies
in patients suffering from severe post-traumatic ALF. Pul-
monary recovery sufficient to wean the patient from ELS
occurred in 85% of patients. Third, our overall hospital
survival rate to discharge in these trauma patients with
severe ALF was 79%, which is markedly better compared
with Injury Severity Score-related mortality rates from the
trauma databank (mean 59%).
Emergency thoracotomy due to fulminate bleeding
had to be performed in nine patients before or after ELS
implantation. Nevertheless, ECMO is a therapy with
potentially serious complications [13]. In this study sam-
ple, no device-related complications including rupture of
the circuits or relevant failure of the oxygenator were
seen. In the past, bleeding disorders, especially in
trauma patients, had been a major complication of ELS
devices related to the requirement for systemic anticoa-
gulation [22]. Further developments in ECMO systems
and the improvement of anticoagulation management of
the circuits (heparin coated) have led to decreased
hemorrhagic complications [2,12]. Heparin-bond circuits
therefore offer supplemental capability in the resuscita-
tion of selected massively injured patients while their
primary injuries have been evaluated and treated [23].
Miniaturized ECMO systems with improved oxygena-
tors, circuits and centrifugal pumps have further mark-
edly decreased hemorrhagic complications, which might
make its implementation possible in patients with a
higher risk of bleeding [13]. However, few data are avail-
able regarding ECMO in trauma patients with increased
risk for bleeding complications. A recent case series
recommends prolonged heparin-free vv-ECMO therapy
in multiple traumatized patients with ALF with coexist-
ing traumatic brain injury and intracranial bleeding.
Neither ECMO-associated bleeding nor clotting of the
extracorporeal circuit occurred and all three patients
survived [24].
By using heparin-coated cannulas and circuits in addi-
tion to a lower systemic anticoagulation regime, the bleed-
ing complication rate of our trauma patients was within
an acceptable range. In addition, patients with coexisting
Table 4 Implantation data, parameters during ELS, complications and outcome
Variable All patients (n = 52) PECLA (n = 26) vv-ECMO (n = 26)
External ELS implantation 25 (48) 7 (26.9) 18 (69.2)
Percutaneous cannulation 51 (98) 25 (96) 26 (100)
Surgical cannula removal 4 (7.7) 4 (15.4) 0 (0)
Pre-ELS mechanical ventilation (days) 3.2 ± 4.1 (0 to 21) 3.7 ± 4.6 (0 to 21) 2.6 ± 3.6 (0 to 16)
Time from trauma to ELS (days) 5.2 ± 7.7 (0 to 38) 5.9 ± 8.1 (0 to 38) 4.5 ± 7.3 (0 to 34)
Duration of ELS (days) 6.9 ± 3.6 (<1 to 19) 7.6 ± 4 (<1 to 19) 6.3 ± 3.1 (<1 to 13)
Flow rate (l/minute) 2.3 ± 0.9 (0.7 to 4.6) 1.7 ± 0.5 (0.7 to 2.9) 3 ± 0.6 (1.8 to 4.6)
Duration of mechanical ventilation (days) 18.4 ± 10.6 (1 to 51) 18.7 ± 10.4 (1 to 49) 18.1 ± 11 (1 to 51)
Cannula-related complications 8 (15.4) 5 (19.2) 3 (11.5)
Renal-replacement therapy 16 (30.8) 9 (34.6) 7 (26.9)
ICU stay (days) 22 (14 to 32) 23 (18 to 35) 17 (13 to 30)
Hospital stay (days) 25 (16 to 41) 25 (21 to 39) 24 (13 to 44)
Surgical procedure 45 (86.5) 21 (80.8) 24 (92.3)
Thoracic surgical procedure 8 (15.4) 4 (15) 4 (15.4)
Surgery with ELS 16 (30.8) 6 (23.1) 10 (38.5)
Weaning from ELS 44 (84.6) 22 (85) 22 (84.6)
Death on ELS system 8 (15.4) 4 (15.4) 4 (15.4)
In-hospital mortality 11 (21.2) 6 (23.1) 5 (19.2)
Data presented as n (%),mean ± standard deviation (minimum to maximum), or median (25th to 75th interquartile range). ELS, extracorporeal lung support;
PECLA, pumpless extracorporeal lung assist; vv-ECMO, veno-venous extracorporeal membrane oxygenation.
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post-traumatic bleeding were treated with initial heparin-
free ECMO, as previously reported from our working
group [18]. But less or no systemic heparin administration
has a potential higher risk for thrombosis of the oxygena-
tor. Accurate monitoring and contingent emergent change
of the oxygenator might therefore be necessary. In this ser-
ies we did not observe this drastic complication. Relevant
bleeding complications at cannulation sites could be trea-
ted in most cases (n = 3) by gentle manual pressure and
only in one patient was surgical correction necessary.
Another serious complication of prolonged peripheral
arterial cannulation remains ischemia of the limb [12,25].
Three patients (19%) with PECLA developed peripheral
ischemia due to arterial cannula placement and required
emergent surgical correction and switch of the cannula-
tion site. The PECLA device with a heparin-coated oxyge-
nation membrane provides sufficient blood flow without
the need for an additional roller pump [14,26,27]. This
device is commonly used for primary pulmonary stabiliza-
tion in peripheral hospitals or even on the battlefield
[27,28].
In the course of the study period we switched to vv-
ECMO to further reduce the complication rate regarding
ischemia or arterial bleeding. vv-ECMO has the advantage
of avoiding arterial vessel complications, including ische-
mia. In trauma patients, arterial vessel access (femoral) is
often limited whereas there are five locations for venous
vessel access to place the ECMO. Only in 12% of our
ECMO patients were bleeding complications due to
venous cannulation recorded and all could be treated con-
servatively. Furthermore, ECMO can also be used in
patients with hemodynamic instability. Adjustment of the
ECMO pump flow provides significantly better oxygena-
tion as well as elimination of carbon dioxide compared
with PECLA. Finally, patients treated with ECMO pre-
sented with worse preimplantation data (higher Lung
Injury Score and Sequential Organ Failure Assessment
score), but their early outcome was slightly better (81%)
compared with patients treated with PECLA (77%). How-
ever, due to a different physiologic concept (low flow of
arterial blood through the membrane), PECLA is predomi-
nantly characterized by efficient carbon dioxide removal
and moderate oxygenation improvement. In trauma
patients with a leading hypercapnic lung failure and with-
out severe hypoxemia, who additionally are suffering from
bleeding complications, PECLA is a suitable alternative to
ECMO since the anticoagulation demand is low.
This single-center study has some limitations. The
main limitation of our study is its retrospective, nonran-
domized design without a control group and the duration
over a 10-year study period. This implies that conclusions
are necessarily limited in their application and causality
cannot be determined. Furthermore, we were not able to
give data on long-term survival. Despite these limitations,
we present a large number of severe trauma patients with
ALF, who were interdisciplinarily treated with two differ-
ent types of ELS in an experienced ECMO center. Finally,
we present prospectively collected data from the Regens-
burg ECMO Registry.
Conclusion
ELS devices are an excellent and life-saving treatment
option in severe thoracic trauma patients with ALF.
Thoracic trauma patients with concomitant refractory
pulmonary failure have a remarkable potential to
recover under ELS. The utilization of the ELS devices
was safe and effective in these severe multiple trauma
patients. Furthermore, we observed no significantly
higher rates of bleeding complications during ELS. But
ELS remains a highly specialized treatment option that
is only available in a few centers and the optimal ther-
apy is complex. An interdisciplinary treatment approach
may facilitate the survival in an experienced trauma cen-
ter. In our current strategy, we encourage the use of
early vv-ECMO support due to reduced complication
rates, better oxygenation and best short-term outcome
in patients with severe post-traumatic ALF.
Key messages
• ELS devices are a life-saving treatment option in
severe thoracic trauma patients with ALF.
• ELS enabled a rapid and sustained improvement of
oxygenation, removal of carbon dioxide and correction
of respiratory acidosis.
• ELS could provide advanced lung-protective ventila-
tion strategies in patients suffering from severe post-
traumatic ALF. Pulmonary recovery sufficient to wean
the patient from ELS occurred in 85% of patients.
• The overall hospital survival rate to discharge in
these multiple trauma patients with severe ALF was
79%.
• Utilization of vv-ECMO support was associated with
acceptable complication rates and provided sufficient
oxygenation.
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